

NC Medicaid and NC Health Choice Pharmacy Prior Approval Request for Continuous Glucose Monitors

Beneficiary Information		
Beneficiary Last Name:	2. First Name:	
3. Beneficiary ID #:4. Beneficia	ary Date of Birth:	5. Beneficiary Gender:
Prescriber Information		
6. Prescribing Provider NPI #:		
7. Requester Contact Information - Name:		Ext
Drug Information		
8. Transmitter/ Sensor Name: □ Dexcom G5 (Sensor only) □ 9 Quantity for Transmitter (G6) (Max 1) 10. Quantity 11. Quantity for Reader(Libre/Libre 2) (Max 1) 12. 0 13. Length of therapy (in days) for Dexcom G6 Transmitter, De □ up to 30 days □ 60 days □ 90 days □ 120 days □ **Max Length of Therapy for Initial Authorization is 180 days** For Dexcom G6 only: 14. Does the beneficiary have a smart device (phone/compute □ Yes □ No (Answering "NO" indicates that the benefician	y for Dexcom (G5/G6) Sensor Quantity for Sensors (Libre/ Libre 2) ecom G5 and G6 Sensor, Libre/Libre 2 R □ 180 days □ 365 days □ Other: er/tablet) to receive transmissions from th	_ (Max 3) (Max 2) Reader and Sensors:
Clinical Information		
For initial therapy, please answer questions 1-11, (max 6 1. Does the beneficiary have a diagnosis of insulin-dependent 2. Has the beneficiary been using a standard BGM (blood gluck therapeutic CGM? ☐ Yes ☐ No 3. Does the beneficiary require two (2) or more insulin injection 4. Does the beneficiary's insulin treatment regimen require free testing? ☐ Yes ☐ No 5. Is the beneficiary and/or caregiver(s) willing and able to use 6. Has the beneficiary had a face-to-face encounter with the tredetermine that criteria one through five (1-5) above have be 7. Does the beneficiary use an external insulin pump? ☐ Yes 8. For coverage of Dexcom G5 or G6; is the beneficiary age 2 9. For coverage of FreeStyle Libre is the beneficiary age 18 yes 10. For coverage of FreeStyle Libre 2 is the beneficiary age 4 11. For coverage of FreeStyle Libre, has the beneficiary tried to be used? ☐ Yes ☐ No If yes, explain ☐ For first reauthorization, please answer questions 12-14, (12. Has the beneficiary been using the CGM as prescribed? ☐ 13. Has the beneficiary been able to improve glycemic control 14. Does the beneficiary continue to use as external insulin pur For Subsequent reauthorizations please answer questions 15. Has the beneficiary had a face-to-face encounter with the control of the process of	diabetes?	is of the second secon
Signature of Prescriber:	nature Mandatory)	Pate:
(Prescriber Sign	iature Manuatory)	

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

Pharmacy PA Call Center: (866) 246-8505